Benchmark Adjusts Bio-Techne Price Target to $75 From $95

Published on 2025-05-08 at 11:55

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Bio-Techne Corporation

Bio-Techne Corporation and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultras sensitive Biomarker Detection	07-15	CI
Bio-Techne Collaborating With Spear Bio to Distribute Immunoassays	07-15	MT
Bio-Techne's Simple Western? Technology Utilized in Recent Fda Approval of Zevaskyn Cell-Based Gene Therapy	07-14	CI
TD Cowen Initiates Bio-Techne at Buy With $65 Price Target	07-09	MT
Bio-Techne Corporation, Q3 2025 Earnings Call, May 07, 2025	06-25
Bio-Techne Corporation and U.S. Pharmacopeia Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development	06-24	CI
Bio-Techne, US Pharmacopeia Partner to Distribute Reference Standards	06-24	MT
Bio-Techne Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10:40 AM	06-10
Bio-Techne Corporation Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 03:45 PM	06-05
Deutsche Bank Adjusts Bio-Techne Price Target to $66 From $70	06-05	MT
Bio-Techne Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 02:40 PM	06-03
Argus Adjusts Price Target on Bio-Techne to $65 From $90	05-30	MT
Wells Fargo Initiates Bio-Techne at Overweight With $59 Price Target	05-30	MT
Bio-Techne Corporation Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10:40 AM	05-13
Bio-Techne Corporation to Showcase Next-Generation Solutions for Gene and Cell Therapy At American Society of Gene & Cell Therapy 2025	05-12	CI
UBS Adjusts Price Target on Bio-Techne to $70 From $95, Maintains Buy Rating	05-09	MT
Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on February 1, 2022.	05-08	CI
Benchmark Adjusts Bio-Techne Price Target to $75 From $95	05-08	MT
Stifel Nicolaus Adjusts Bio-Techne Price Target to $60 From $75, Maintains Hold Rating	05-08	MT
Bio-Techne Collaborates With Genome Engineering Firm Kytopen	05-08	MT
Kytopen Corp. and Bio-Techne Corporation Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing	05-08	CI
Citigroup Adjusts Bio-Techne Price Target to $55 From $70, Maintains Neutral Rating	05-08	MT
Deutsche Bank Adjusts Bio-Techne Price Target to $70 From $84, Maintains Buy Rating	05-08	MT
RBC Cuts Price Target on Bio-Techne to $63 From $72, Keeps Sector Perform Rating	05-08	MT
Evercore ISI Cuts Price Target on Bio-Techne to $60 From $70	05-07	MT